Agios ClarIDHy

Please note: The Agios ClarIDHy trial met its recruitment target on 5th February 2019, and so is no longer recruiting new patients.

The ClarIDHy clinical trial is testing the safety and efficacy of an investigational medication, AG-120, in eligible patients with IDH1-mutated advanced cholangiocarcinoma.

AG-120: Investigational medication for IDH1-mutated advanced cholangiocarcinoma

AG-120, developed by Agios, is a targeted therapy that targets cancer cells with a mutation in a gene called IDH1. Among patients with cholangiocarcinoma, 13%-15% may have an IDH1 mutation in their tumour.

March 2018: This international trial is now open and recruiting at the following centres in the UK:

The Christie, Manchester – Professor Juan Valle
Direct e-mail:
PA: Lindsey Duncan:
Tel 0161 446 8106
Fax 0161 446 3468
e-mail: lindsey.duncan@christie.nhs

UCL, London – Professor John Bridgewater
Professor John Bridgewater’s contact details:
Tel: 020 3447 9093
Fax: 020 3447 9055

Royal Free London NHS Foundation Trust – Dr Roopinder Gillmore,

Agios Pharmaceuticals, Inc identifier: NCT02989857

For more information on this trial go to:


The following European sites are also currently recruiting:


  • Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer (Marc Pracht)
  • Hopital Jean Minjoz (Christophe Borg)
  • Institut Gustave Roussy Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest (Marianne Fonck)
  • Institut Gustave Roussy (David Malka)


  • Hospital Universitario Vall d’Hebron – PPDS (Teresa Macarulla Mercade)
  • Hospital Universitario 12 de Octubre (Jorge Adeva Alfonso)
  • Hospital Universitario HM Sanchinarro – CIOCC (Antonio Cubillo Gracián)
  • Hospital General Universitario Gregorio Marañon (Andres Muñoz)
  • Hospital Universitario Marques de Valdecilla (Fernando Rivera)


  • Ospedale San Raffaele S.r.l. – PPDS (Luca Gianni)

Sites are also currently recruiting in the USA and South Korea.

Back to previous page